Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide to reduce postoperative digestive leakage after CRS plus HIPEC
2019-002507-18Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Nov 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in peritoneal carcinomatosis (PC), primary peritoneal cancer (PPC) and peritoneal malignancy (PM) comparing Pasireotide with Placebo (2 arms). Primary endpoint: Clinically relevant postoperative digestive leakage rate at 97 days. Started Nov 2019; status: completed.
02
Drugs
pasireotide LAR
03
Conditions
peritoneal carcinomatosis (PC)primary peritoneal cancer (PPC)peritoneal malignancy (PM)
Beyond the preview
Go deeper on 2019-002507-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002507-18.